Portfolio and Platform Strategy

Portfolio and Platform Strategy

  • Defined Health works with many emerging biotech companies to prioritise pipeline portfolios and define pathways to value inflection
  • Typically, these programs are at pre-clinical to early clinical development (Phase I-Phase 2a) so opportunity remains to shape the development program to maximise potential for clinical and commercial success
  • Output often includes a definition of therapeutic strategy and best transaction model going forward

More Information